Oxytocin is the drug with greatest near-term potential to address autism. It has successfully treated core symptoms of autism in placebo-controlled clinical trials on four continents. The drug’s use has been largely limited to medical research at universities; pharmaceutical companies have been reluctant to develop it for wider use because the current form of the drug has no patent protection.
Pastorus, Inc. is a New York City-based biotechnology company developing improved, patent-protected forms of oxytocin and other drugs to treat autism. Recent research has demonstrated the potential to amplify oxytocin’s favorable effects with a combination product – for which Pastorus has a pending patent application. Further details are available under confidentiality.
A particular need exists in autism, a disorder that challenges the families of over 3 million individuals in the U.S. and tens of millions worldwide, with no drugs approved to treat its core symptoms.
Pastorus has a core team of three physician-neuroscientists, each with over 20 years of industry experience. They collaborate with successful experts in regulatory, clinical, manufacturing and other domains; people who have developed some of the leading drugs on the market.